查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球动物生物技术市场-2022-2029
市场调查报告书
商品编码
1129273

全球动物生物技术市场-2022-2029

Global Animal Biotechnology Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

基因工程的最新进展预计将推动市场增长。

近年来基因工程的研究和发展扩大了生物技术在畜牧业的研究和应用领域。为食用而饲养的动物，如牛和鸡，其肉和奶中含有优质蛋白质、必需氨基酸、矿物质、脂肪、易吸收的维生素、微量碳水化合物和其他生物活性物质。畜牧业利用生物技术促进品种开发，以改善动物福利和健康，提高生育能力，并提高动物衍生产品的营养质量和安全性。人工授精、体外受精、体细胞核移植等多种生物技术提高了动物的生育能力。例如，使用 DNA 标记来阐明动物的遗传特征并预测它们的能力在动物生物技术中很有用。标记辅助选择是一种间接选择有趣性状的遗传决定因素的技术。许多性状由多个基因座控制，每个基因座称为数量性状基因座，并有助于性状变异。如果在胚胎中发现重要的数量性状基因座，生产者可以选择转移或丢弃胚胎。只有与基因或目标属性密切相关的遗传标记才能保证实际的育种成功。

此外，重组 DNA 技术也是一种将称为 rDNA 的重组 DNA 分子插入宿主生物体以产生对动物有益的独特基因融合的方法。 DNA疫苗可用于生产动物疫苗，产生多个基因拷贝或将外源基因插入其他物种以赋予新的特征，例如抗生素抗性，从而产生有效且持久的细胞，可引发性免疫反应。因此，从上述陈述来看，预计市场将在预测期内受到驱动。

限制

动物生物技术产品的高成本、与动物生物技术产品相关的伦理问题、缺乏熟练的专业人员进行诊断测试等是预计在预测期内阻碍市场的一些因素。是一个因素。

行业分析

动物生物技术市场根据各种行业因素（包括搬运工五力、供应链、定价分析和监管批准）对市场进行了深入分析。

COVID-19 影响分析

COVID-19 大流行对市场产生了适度的影响。冠状病毒大流行使生物技术研究的潜在好处和陷阱成为人们关注的焦点。此类研究可用于开发抗击疾病的医学疗法、更健康的作物和牲畜，并可能用于製造生物武器。世界各地的研究人员都在积极抗击这一流行病。他们正在使用诸如开发廉价的诊断方法、重新利用现有的抗病毒药物、发现新药以及製造可靠和有效的疫苗等技术。

此外，生物技术还可以生产可以有意释放到环境中的转基因生物，例如用于蚊子控制。例如，基因组工程技术的发展，如 CRISPR（成簇的规则间隔的短回文重复序列）和 Cas9（CRISPR 相关蛋白 9），使得创建基因驱动成为可能。使用这种方法，所需的遗传改变可以在几代人的整个人群中迅速传播。该技术可以通过使蚊子对引起这些疾病的寄生虫产生抵抗力或完全消灭携带疾病的蚊子种群来治疗疟疾和登革热等媒介人类疾病。另一方面，受疫情影响，中小型企业对动物医院的探访也面临挑战。因此，大流行扰乱了供应链。因此，COVID-19 大流行正在影响市场。但是，预计情况将在预测期内逐渐改善。

全球动物生物技术市场报告将提供对大约 45 多个市场数据表、40 多个数字和 180 页的访问。

内容

第一章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 基因工程的进步有望推动市场增长
    • 限制因素
      • 预计动物生物技术产品的高成本将在预测期内受到阻碍。
    • 市场机会
    • 影响分析

第五章行业分析

  • 波特的五种力量
  • 未满足的需求
  • 供应链
  • 定价分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按动物类型

  • 牲畜
    • 鱼
    • 家禽
    • 猪
    • 牛
    • 绵羊/山羊
    • 其他
  • 伴侣
      • 狗
      • 猫科
      • 马
      • 水生动物
      • 鸟类
      • 其他

第 8 章按产品类型

  • 药物
  • 疫苗接种
  • 诊断试剂
  • 基因和生殖产品
  • 其他

第 9 章。按应用程序

  • 动物疾病诊断
  • 动物疾病的治疗
  • 动物预防医学
  • 药物开发
  • 其他

第 10 章，最终用户

  • 兽医医院和诊所
  • 实验室
  • 内部检查
  • 其他

第 11 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 12 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准
  • 值得关注的重点公司列表

第 13 章公司简介

  • 勃林格殷格翰有限公司
    • 公司简介
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Merck & Co.,Inc.
  • Virbac
  • Elanco
  • Zoetis
  • Biogenesis Bago
  • Idexx Laboratories
  • Heska Corporation
  • Indian Immunologicals Ltd.
  • HESTER BIOSCIENCES LIMITED

第 14 章全球动物生物技术市场 - DataM

简介目录
Product Code: DMBT5846

Market Overview

Animal Biotechnology Market size was valued US$ YY million in 2021 and is estimated to reach US$ YY million by 2029, growing at a CAGR of YY % during the forecast period (2022-2029).

Animal biotechnology refers to using engineering, science, and technology to modify and improve living organisms such as animals. Animal biotechnology can also be further explained as part of biotechnology, where molecular biotechnology techniques are used to genetically manipulate or modify the genome of various animals to improve their suitability for various applications such as pharmaceutical, industrial or agricultural applications. In the same case, animal biotechnology uses multiple methods to diagnose the various diseases in animals, allow the treatment of these diseases through multiple therapeutic options and the development of veterinary drugs, and the preventive care of animals through veterinary vaccines. The vaccination process is a highly effective and crucial tool for preventing animal diseases and promoting animal health and welfare, safe food production and public health.

Market Dynamics

Recent advances in genetic engineering are expected to drive market growth.

Recent developments in genetic engineering have widened the area of biotechnology research and application in farm animals. Animals raised for food, such as cattle and poultry, provide high-quality protein, essential amino acids, minerals, fats, easily absorbed vitamins, trace amounts of carbohydrates, and other bioactive substances in their meat and milk. In the livestock industry, biotechnology is being used to accelerate breed development for greater animal welfare and health, increased reproduction, and improved nutritional quality and safety of products obtained from animals. Through a range of biotechnological techniques, such as artificial insemination, in-vitro fertilization, and somatic cell nuclear transfer, animal breeding stock is thus improved. For instance, using DNA markers to describe an animal's genetic make-up and predict its performance is useful in animal biotechnology. Marker-assisted selection is a technique for indirectly selecting a genetic determinant of an interesting feature. Many traits are governed by multiple genetic loci, each of which is referred to as a quantitative trait locus and contributes to the trait's variation. The producer may be given the option of transferring or discarding the embryo if significant quantitative characteristic loci are found in the embryo. Only genetic markers strongly related to the genes or objective attributes can ensure successful breeding in practice.

Additionally, recombinant DNA technology is another method that allows the creation of unique genetic fusions advantageous to animals by inserting a recombined DNA molecule known as rDNA into a host organism. DNA vaccines can elicit potent, long-lasting cellular immune responses because it enables the production of numerous copies of genes and the insertion of foreign genes into other species to impart new traits like antibiotic resistance and the production of animal vaccines. Thus, from the above statements, the market is expected to drive in the forecast period.

Restraint:

The high cost of animal biotechnology products, ethical concerns related to animal biotechnology products and lack of skilled professionals to perform diagnostic tests are some factors the market is expected to get hampered in the forecast period.

Industry Analysis

The animal biotechnology market provides in-depth analysis of the market based on various industry factors such as porter five forces, supply chain, pricing analysis, regulatory approvals etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted the market. The coronavirus pandemic has brought biotechnology research's potential benefits and pitfalls into focus. Although such research can be used to develop medical countermeasures to combat disease and to develop healthier crops and livestock, it can also be used to create biological weapons. Researchers from all across the world are aggressively battling the pandemic. They've utilized several technologies to develop affordable diagnostics, repurpose current antivirals, find novel medicines, and manufacture certain and efficient vaccinations.

Additionally, genetically modified organisms that can be purposefully released into the environment for things like mosquito control can be made via biotechnology. For instance, developments in genome engineering technologies, like clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (Cas9), have made it possible to create gene drives. This method enables desired genetic alterations to spread quickly throughout a population over several generations. This technique can cure vector-borne human diseases such as malaria and dengue fever by either making mosquitoes resistant to the parasites that cause these diseases or completely wiping out disease-carrying mosquito populations. In contrast, medium- and small-sized enterprises had challenges due to the pandemic's restrictions on veterinary clinic visits. Therefore, the pandemic is interrupting the supply chain. Thus, the COVID-19 pandemic has affected the market. However, the situation is expected to improve gradually in the forecast period.

Segment Analysis

Vaccinations segment is expected to hold the largest market share in animal biotechnology market.

The vaccinations segment accounted for the largest market share in 2021. The segment is benefited from the rising incidence of animal diseases, which naturally spread from animals to humans through consumption of contaminated food and water or direct contact with plagued individuals. Animal illness burden can be decreased through vaccination, which is also a key component of disease prevention and control. Moreover, new vaccine manufacturing techniques have emerged due to advances in technology, medicine, and basic scientific fields like immunology, molecular biology, microbiology, and biochemistry. The application of newer vaccination theories has been aided by genetic engineering, proteomics, and other cutting-edge technologies, leading to the discovery of new ruminant vaccines and the improvement of current ones. The next generation of vaccinations, which are being examined as potential alternatives to traditional immunizations, include subunit, recombinant, DNA, and vector.

Additionally, there are increasing vaccine launches for animals. For instance, Boehringer Ingelheim India introduced VAXXITEK HVT+IBD, a vaccine for poultry, in May 2021. All varieties of producing hens, including broiler, layer, and breeder chickens, are guaranteed lifelong protection by a novel recombinant vaccine called VAXXITEK HVT+IBD. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global animal biotechnology market

In 2021, North American animal biotechnology accounted for the highest revenue share in the global market. The increasing prevalence of zoonotic diseases, advances in genetic engineering in animals, and increasing initiatives and campaigns to promote animal health in the region are driving the market in the forecast period. For instance, according to Dr. Mark Walton, Chief Technology Officer at AquaBounty Technologies, AquAdvantage Salmon (AAS) presents several opportunities for addressing the impending fish shortage and developing a variety of nutrient-rich foods. According to Dr. Walton, AAS has faster development and improved feed efficiency, so it requires less time in water and feeds to get a kilo of proteins. The scientist added that AAS genetics is crucial to the system's profitability and that the AquAdvantage system is witnessing a significant rise in investment. The scientist asserted that the spread of salmon farming in recirculating aquaculture systems on land in the US and internationally would be significantly aided by AquAdvantage.

Furthermore, the Canadian Agricultural Partnership will start contributing up to $4 million in January 2021 to give farmers better access to veterinary services when and when they need them. To enable a collaborative and coordinated approach to transform technologies in the field of veterinary vaccines, biologicals, and diagnostics, TRPVB is a cooperation initiative between the Department of Biotechnology, India, and TANUVAS-Chennai. Therefore, it has increased the demand for animal biotechnology in the region. Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the animal biotechnology market are Boehringer Ingelheim GmbH, Merck & Co.,Inc., Virbac, Elanco, Zoetis, Biogenesis Bago, Idexx Laboratories, Heska Corporation, Indian Immunologicals Ltd. and HESTER BIOSCIENCES LIMITED.

Boehringer Ingelheim GmbH:

Overview:

Boehringer Ingelheim is one of Germany's leading contract manufacturers of biopharmaceuticals based on cell cultures and microorganisms. The company is divided into three business areas: human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing. Moreover, in the animal health sector, Boehringer Ingelheim is one of the world's leading suppliers of vaccines, therapeutics and preventive products that protect animals from disease and pain. In addition, the company achieved net sales of around 4.3 billion euros in the animal health sector in 2021, corresponding to 21 percent of the total net sales. The company's integrated product portfolio includes more than 200 products for dogs, cats, horses, pigs, cattle and poultry. The parasiticides NEXGARD and FRONTLINE for dogs and cats, HEARTGARD for dogs, and the pig vaccines INGELVAC CIRCOFLEX/ FLEXBOMBO are among the best-known brands. Furthermore, the company has an established global animal health innovation network with 18 R&D sites worldwide. The focus is innovative vaccines and parasiticides to protect livestock and companion animals and therapeutics for treating chronic diseases and other debilitating conditions.

Product Portfolio:

Ingelvac PRRS MLV: Ingelvac PRRS MLV is a modified live PRRS vaccine that is safe in pigs, gilts, and sows at all stages of production in PRRS-positive herds. It offers cross-protection against heterologous challenges; (including the Lelystad virus) and has significantly reduced reproductive disorders and respiratory disease due to the PRRS virus.

  • Trusted and field-proven
  • Cost-effective
  • Unique in its ability to be used in pigs (3 weeks or older), gilts, and sows at ANY stage of production
  • Available in three convenient sizes (10, 50, and 250 doses)

The global animal biotechnology market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Recent advances in genetic engineering are expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. The high cost of animal biotechnology products is expected to get hampered in the forecast period.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Unmet Needs
  • 5.3. Supply Chain
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Animal Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Type
    • 7.1.2. Market Attractiveness Index, By Animal Type Segment
  • 7.2. Livestock*
      • 7.2.1.1. Fish
      • 7.2.1.2. Poultry
      • 7.2.1.3. Swine
      • 7.2.1.4. Cattle
      • 7.2.1.5. Sheep & Goats
      • 7.2.1.6. Others
      • 7.2.1.6.1. Introduction
      • 7.2.1.6.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Companion
      • 7.3.1.1. Canine
      • 7.3.1.2. Feline
      • 7.3.1.3. Equine
      • 7.3.1.4. Aquatic
      • 7.3.1.5. Avian
      • 7.3.1.6. Others

8. By Product Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 8.1.2. Market Attractiveness Index, By Product Type Segment
  • 8.2. Drugs*
      • 8.2.1.1. Introduction
      • 8.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Vaccinations
  • 8.4. Diagnostic Tests
  • 8.5. Genetic & Reproductive Products
  • 8.6. Others

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application Segment
  • 9.2. Diagnosis of Animal Diseases*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Treatment of Animal Diseases
  • 9.4. Preventive Care of Animals
  • 9.5. Drug Development
  • 9.6. Others

10. By End user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user Segment
  • 10.2. Veterinary Hospitals & Clinics*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Laboratories
  • 10.4. In-house Testing
  • 10.5. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animal Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Boehringer Ingelheim GmbH*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Merck & Co.,Inc.
  • 13.3. Virbac
  • 13.4. Elanco
  • 13.5. Zoetis
  • 13.6. Biogenesis Bago
  • 13.7. Idexx Laboratories
  • 13.8. Heska Corporation
  • 13.9. Indian Immunologicals Ltd.
  • 13.10. HESTER BIOSCIENCES LIMITED

LIST NOT EXHAUSTIVE

14. Global Animal Biotechnology Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Applications
  • 14.3. Contact Us